BCL2 and cancer: For instance, one of the most studied senolytics is Navitoclax (ABT-263),164 a BH3 mimetic targeting the antiapoptotic proteins BCL2/BCL-XL/BCL-W, which has been confirmed to effectively eliminate TISnt cancer cells in doxorubicin-treated mice exhibiting breast cancer76,165 and radiotherapy-treated mice exhibiting glioma.166 These preclinical studies showed that senolytics kill TISnt cancer cells by inhibiting pro-survival signals, which can also reduce tumor recurrence.